NRXP
NRx Pharmaceuticals, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-4.48
P/S
31.75
EV/EBITDA
-0.95
DCF Value
$0.78
FCF Yield
-36.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
50.6%
Operating Margin
-1322.0%
Net Margin
-2336.6%
ROE
111.7%
ROA
-220.9%
ROIC
105.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $983.0K | $360.0K | $0.01 |
| FY 2025 | $1.2M | $-28.6M | $-1.34 |
| Q3 2025 | $242.0K | $-5.9M | $-0.27 |
| Q2 2025 | $0.00 | $-17.6M | $-0.98 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.83
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.